<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01700439</url>
  </required_header>
  <id_info>
    <org_study_id>2011-02</org_study_id>
    <nct_id>NCT01700439</nct_id>
  </id_info>
  <brief_title>Surgical Treatment of Aortic Stenosis With a Next Generation, Rapid Deployment Surgical Aortic Valve</brief_title>
  <acronym>TRANSFORM™</acronym>
  <official_title>Multi-CenTer Experience With the Rapid Deployment EDWARDS INTUITY Valve System FOR Aortic Valve ReplaceMent</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Edwards Lifesciences</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Edwards Lifesciences</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of the clinical study is to prove that the heart valve device is safe, effective,
      and performs as intended.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a prospective, non-randomized, multi-center trial. Up to 950 subjects will be
      enrolled at up to 35 centers in the US. After replacement of their aortic heart valve with
      the EDWARDS INTUITY valve system, each patient will have routine follow-up tests at the
      following intervals: discharge, 3 months, 1 year, and annually thereafter for a minimum of
      five years.
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>September 2012</start_date>
  <completion_date type="Anticipated">November 2021</completion_date>
  <primary_completion_date type="Actual">August 12, 2016</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Late Adverse Events Divided by Late Patient Years (Expressed as a Percentage)</measure>
    <time_frame>Events occurring ≥ 31 days and up through 2 years post-implant</time_frame>
    <description>Late patient years are calculated from 31 days post-implant to the date of the last follow-up visits (or contact) or adverse events. Late Patient year calculation:[(Number of late adverse events/sum of late patient years) x 100]</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentage of Subjects With Edwards INTUITY Surgical Aortic Heart Valve Device Technical Success</measure>
    <time_frame>Day of procedure</time_frame>
    <description>Device technical success is defined as the successful delivery and deployment of the aortic trial heart valve with maximum of two attempts and subject leaving the operating room (OR) with valve in place.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Subjects With Edwards INTUITY Surgical Heart Valve Procedural Success</measure>
    <time_frame>Day of procedure through discharge or 10 days post index procedure, whichever comes first.</time_frame>
    <description>Procedural success is defined as device technical success followed by the absence of adverse events resulting in device reoperation implant of permanent pacemaker (with baseline sinus rhythm and no other pre-existing conduction issues), or valve-related death within discharge or 10 days post index procedure, whichever comes first.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Average Amount of Time Subject Spent on Cardiopulmonary Bypass</measure>
    <time_frame>Day of procedure</time_frame>
    <description>Surgical and hospitalization factors - Cardiopulmonary bypass time</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Average Subject Time on Cardiopulmonary Cross Clamp</measure>
    <time_frame>Day of procedure</time_frame>
    <description>Surgical and hospitalization factors - Cardiopulmonary cross clamp time</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Average Number of Days Subjects Were in the Intensive Care Unit (ICU)</measure>
    <time_frame>Day of procedure through discharge from the hospital</time_frame>
    <description>Length of time surgical subjects were in the intensive care unit (ICU) after their heart valve replacement procedure.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Subject's Percentage of Change at 1 Year From Baseline in New York Heart Association (NYHA) Class</measure>
    <time_frame>Baseline and one year follow-up</time_frame>
    <description>The New York Heart Association (NYHA) functional classification system relates symptoms to everyday activities and the patient's quality of life. Class I. Patients with cardiac disease but without resulting limitation of physical activity.
Class II. Patients with cardiac disease resulting in slight limitation of physical activity. They are comfortable at rest.
Class III. Patients with cardiac disease resulting in marked limitation of physical activity. They are comfortable at rest.
Class IV. Patients with cardiac disease resulting in inability to carry on any physical activity without discomfort.
Symptoms of heart failure or the anginal syndrome may be present even at rest.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Subject's Average Gradient Measurements at 1 Year</measure>
    <time_frame>1 Year follow-up</time_frame>
    <description>Hemodynamic performance - Mean and peak gradients evaluated by echocardiography</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Subject's Effective Orifice Area (EOA) Measurement at 1 Year</measure>
    <time_frame>1 Year follow-up</time_frame>
    <description>Hemodynamic performance - Effective Orifice Area (EOA) evaluated by echocardiography</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Subject's Effective Orifice Area Index (EOAI) Measurement at 1 Year</measure>
    <time_frame>1 year follow-up</time_frame>
    <description>Hemodynamic performance - Effective Orifice Area Index evaluated by echocardiography</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Subject's Performance Index Measurement at 1 Year</measure>
    <time_frame>1 Year follow-up</time_frame>
    <description>Hemodynamic performance - Performance Index evaluated by echocardiography</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Subject's Cardiac Output Measurement at 1 Year</measure>
    <time_frame>1 Year follow-up</time_frame>
    <description>Hemodynamic performance - Cardiac Output evaluated by echocardiography</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Subject's Cardiac Index Measurement at 1 Year</measure>
    <time_frame>1 Year follow-up</time_frame>
    <description>Hemodynamic performance - Cardiac index evaluated by echocardiography</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Amount of Aortic Valvular Regurgitation in Subjects at 1 Year by Valve Size</measure>
    <time_frame>1 Year follow-up</time_frame>
    <description>Hemodynamic performance - Aortic valvular regurgitation evaluated by echocardiography</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Subject's Average Score at Baseline and 1 Year on the Quality of Life Survey</measure>
    <time_frame>Baseline and one year follow-up</time_frame>
    <description>The Medical Outcomes Study Short-Form 12 (SF-12) - physical and metal states. The SF-12 questionnaire scale ranges from 100, which reflects the best health status to 0, which reflects the worst health status.</description>
  </other_outcome>
  <other_outcome>
    <measure>Subject's Average White Blood Cell Count at 1 Year</measure>
    <time_frame>1 Year follow-up</time_frame>
    <description>Laboratory analysis of White Blood Cell Count on blood drawn from subject.</description>
  </other_outcome>
  <other_outcome>
    <measure>Subject's Average Red Blood Cell Count at 1 Year</measure>
    <time_frame>1 Year follow-up</time_frame>
    <description>Laboratory analysis of Red Blood Cell Count of blood drawn from subject.</description>
  </other_outcome>
  <other_outcome>
    <measure>Subject's Average Hematocrit Percentage at 1 Year</measure>
    <time_frame>1 Year follow-up</time_frame>
    <description>Laboratory analysis of Hematocrit of blood drawn from subject.</description>
  </other_outcome>
  <other_outcome>
    <measure>Subject's Average Hemoglobin Percentage at 1 Year</measure>
    <time_frame>1 Year follow-up</time_frame>
    <description>Laboratory analysis of Hemoglobin of blood drawn from subject.</description>
  </other_outcome>
  <other_outcome>
    <measure>Subject's Average Plasma Free Hemoglobin at 1 Year</measure>
    <time_frame>1 Year follow-up</time_frame>
    <description>Laboratory Analysis of Plasma Free Hemoglobin of blood drawn from subject.</description>
  </other_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">934</enrollment>
  <condition>Aortic Valve Stenosis</condition>
  <condition>Aortic Valve Stenosis With Insufficiency</condition>
  <condition>Regurgitation, Aortic Valve</condition>
  <condition>Aortic Valve Incompetence</condition>
  <arm_group>
    <arm_group_label>EDWARDS INTUITY valve</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>All subjects enrolled into the study are implanted with the EDWARDS INTUITY Valve System.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>EDWARDS INTUITY valve</intervention_name>
    <description>Surgical replacement of the aortic valve with the EDWARDS INTUITY valve.</description>
    <arm_group_label>EDWARDS INTUITY valve</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Inclusion Criteria - Subjects will be required to meet all inclusion criteria:

               1. Male or female, age 18 years or older

               2. Has aortic stenosis or stenosis-insufficiency of an aortic valve requiring a
                  planned replace-ment as indicated in the preoperative evaluation

               3. Is scheduled to undergo planned aortic valve replacement with or without
                  concomitant coronary bypass surgery

               4. Provide written informed consent

               5. Geographically stable and agrees to attend follow-up assessments until all
                  subjects have completed 5 years of follow up

        Exclusion Criteria:

          -  Exclusion Criteria - Subjects will not be eligible for trial participation if any of
             the following criteria are present:

               1. Pure aortic insufficiency

               2. Requires emergency surgery

               3. Previous aortic valve replacement

               4. Had prior mitral, tricuspid or pulmonic valve surgery, which included implant of
                  a bioprosthetic valve, mechanical valve, or annuloplasty ring that will remain in
                  situ

               5. Requires multiple valve replacement/repair

               6. Requires a surgical procedure outside of the cardiac area (e.g., vascular
                  endarterectomy, vascular bypass, tumor removal)

               7. Aneurysm of the aortic root and/or ascending aorta requiring surgical
                  intervention

               8. Active endocarditis/myocarditis or endocarditis/ myocarditis within 3 months
                  prior to the scheduled AVR surgery

               9. Myocardial infarction (MI) within thirty (30) days prior to valve replacement
                  surgery

              10. Renal insufficiency as determined by creatinine ≥ 2.5 mg/dL at screening or
                  end-stage renal disease requiring chronic dialysis

              11. Hyperparathyroidism

              12. MRI or CT-scan confirmed cerebrovascular accident (CVA), or transient ischemic
                  attack (TIA) within 6 months (180 days) of the procedure

              13. Presence of non-cardiac disease limiting life expectancy to less than 12 months

              14. Hypertrophic obstructive cardiomyopathy (HOCM)

              15. Left ventricular ejection fraction ≤ 25%

              16. Documented history of substance (drug or alcohol) abuse within the last 5 years

              17. Echocardiographic evidence of an intra-cardiac mass, thrombus, or vegetation

              18. Hemodynamic or respiratory instability requiring inotropic support, mechanical
                  circulatory support, or mechanical ventilation within 30 days prior to the
                  procedure

              19. Pregnancy, lactation, or planning to become pregnant;

              20. Currently incarcerated or unable to give voluntary informed consent

              21. Leucopenia (WBC &lt; 3.5x 103/µL), or acute anemia (Hgb &lt; 10.0 gm/dL or 6 mmol/L),
                  or thrombocytopenia (platelet count &lt; 50x 103/µL), or history of bleeding
                  diathesis or coagulopathy

              22. History of myxomatous disease/connective tissue disorders (e.g., Marfan's
                  Syndrome)

              23. Current or recent participation (within 6 weeks prior to surgery) in an
                  investigational drug or device trial

                  _____

                  Intra-operative Exclusion Criteria

              24. Anatomic variances which contraindicate implant of the trial valve, such as:

                    1. anomalous coronary arteries

                    2. annular deformation or extensive calcification of the annulus or aortic root
                       which cannot be removed

                    3. significant calcium on the anterior mitral leaflet

                    4. pronounced septal calcification

                    5. position of coronary ostia relative to Model 8300ACD valve that would result
                       in obstruction of blood flow

              25. Available devices are not suitably sized for the subject's annulus
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Glenn Barnhart, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Swedish Medical Center</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Walter Randolph Chitwood, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>East Carolina University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Keck Hospital of University of Southern California</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90033</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of California Los Angeles</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90095</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hoag Memorial Hospital Presbyterian</name>
      <address>
        <city>Newport Beach</city>
        <state>California</state>
        <zip>92663</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Stanford University</name>
      <address>
        <city>Palo Alto</city>
        <state>California</state>
        <zip>94304</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mercy General Hospital</name>
      <address>
        <city>Sacramento</city>
        <state>California</state>
        <zip>95819</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Florida Hospital</name>
      <address>
        <city>Orlando</city>
        <state>Florida</state>
        <zip>32803</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Northwestern University</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60611</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Beth Israel Deaconess Medical Center</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02215</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The University of Michigan Medical School</name>
      <address>
        <city>Ann Arbor</city>
        <state>Michigan</state>
        <zip>48109</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Washington University - Barnes Jewish Hospital</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cooper University Hospital</name>
      <address>
        <city>Camden</city>
        <state>New Jersey</state>
        <zip>08103</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>North Shore Long Island Jewish Health System</name>
      <address>
        <city>Manhasset</city>
        <state>New York</state>
        <zip>11030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>New York University Medical Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10016</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Columbia University</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10032</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mission Hospital</name>
      <address>
        <city>Asheville</city>
        <state>North Carolina</state>
        <zip>28801</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Duke University Medical Center</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27705</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>East Carolina University</name>
      <address>
        <city>Greenville</city>
        <state>North Carolina</state>
        <zip>27834</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Good Samaritan Hospital</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45220</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cleveland Clinic Foundation</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44195</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pinnacle Health at Harrisburg Hospital</name>
      <address>
        <city>Harrisburg</city>
        <state>Pennsylvania</state>
        <zip>17010</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital of the University of Pennsylvania</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Pittsburgh Medical Center</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15213</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Baptist Memorial Hospital</name>
      <address>
        <city>Memphis</city>
        <state>Tennessee</state>
        <zip>38120</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Thomas Health</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37205</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medical City Dallas Hospital</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75230</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Baylor College of Medicine</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Heart Hospital Baylor Plano</name>
      <address>
        <city>Plano</city>
        <state>Texas</state>
        <zip>75093</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Swedish Medical Center</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98122</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Aurora St Luke's Medical Center</name>
      <address>
        <city>Milwaukee</city>
        <state>Wisconsin</state>
        <zip>53215</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>https://professional.heart.org/professional/General/UCM_423811_Classification-of-Functional-Capacity-and-Objective-Assessment.jsp</url>
    <description>New York Heart Association Classification</description>
  </link>
  <verification_date>March 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 19, 2012</study_first_submitted>
  <study_first_submitted_qc>October 2, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 4, 2012</study_first_posted>
  <results_first_submitted>September 22, 2017</results_first_submitted>
  <results_first_submitted_qc>December 12, 2017</results_first_submitted_qc>
  <results_first_posted type="Actual">December 13, 2017</results_first_posted>
  <last_update_submitted>March 12, 2018</last_update_submitted>
  <last_update_submitted_qc>March 12, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">March 14, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Aortic valve</keyword>
  <keyword>Heart valve</keyword>
  <keyword>Tissue valve</keyword>
  <keyword>Bioprosthesis</keyword>
  <keyword>Valve disorder</keyword>
  <keyword>Valve disease</keyword>
  <keyword>Cardiac surgery</keyword>
  <keyword>Less invasive cardiac surgery</keyword>
  <keyword>Aortic valve stenosis</keyword>
  <keyword>Aortic valve regurgitation</keyword>
  <keyword>Bovine pericardium</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Constriction, Pathologic</mesh_term>
    <mesh_term>Aortic Valve Stenosis</mesh_term>
    <mesh_term>Aortic Valve Insufficiency</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <pre_assignment_details>934 participants were considered enrolled; however, data are only available for 889 participants.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Edwards INTUITY Surgical Aortic Heart Valve</title>
          <description>Subjects who received an INTUITY study surgical aortic heart valve.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="889"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Study Valve Group</title>
              <participants_list>
                <participants group_id="P1" count="839">Received the Edwards INTUITY surgical aortic heart valve.</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>Discharge</title>
              <participants_list>
                <participants group_id="P1" count="831"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>3 Month</title>
              <participants_list>
                <participants group_id="P1" count="778"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>1 Year</title>
              <participants_list>
                <participants group_id="P1" count="573"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>2 Year</title>
              <participants_list>
                <participants group_id="P1" count="215"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="889"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Edwards INTUITY Surgical Aortic Heart Valve</title>
          <description>Subjects who received an Edwards INTUITY surgical aortic heart valve.</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="839"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="73.5" spread="8.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <population>839 are analyzed to date</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="298"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="541"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="773"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="63"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="934"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Late Adverse Events Divided by Late Patient Years (Expressed as a Percentage)</title>
        <description>Late patient years are calculated from 31 days post-implant to the date of the last follow-up visits (or contact) or adverse events. Late Patient year calculation:[(Number of late adverse events/sum of late patient years) x 100]</description>
        <time_frame>Events occurring ≥ 31 days and up through 2 years post-implant</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Edwards INTUITY Surgical Aortic Heart Valve</title>
            <description>Subjects who received an Edwards INTUITY surgical aortic heart valve.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Late Adverse Events Divided by Late Patient Years (Expressed as a Percentage)</title>
          <description>Late patient years are calculated from 31 days post-implant to the date of the last follow-up visits (or contact) or adverse events. Late Patient year calculation:[(Number of late adverse events/sum of late patient years) x 100]</description>
          <units>Percentage of events/late patient years</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="839"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>All cause mortality</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Valve related mortality</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Study valve reoperation</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Study valve explant</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Thromboembolism</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Valve thrombosis</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Endocarditis</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>All bleeding</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Major bleeding</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>All paravalvular leak</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Major paravalvular leak (PVL)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hemolysis</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Non-structural valve dysfunction other than PVL</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Valve migration/embolization</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Valve malposition</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Valve instability</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Valve dislodgement</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Structural valve deterioration</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Conduction defects</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Conduction defects with permanent pacemaker</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Conduction defects without permanent pacemaker</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Subjects With Edwards INTUITY Surgical Aortic Heart Valve Device Technical Success</title>
        <description>Device technical success is defined as the successful delivery and deployment of the aortic trial heart valve with maximum of two attempts and subject leaving the operating room (OR) with valve in place.</description>
        <time_frame>Day of procedure</time_frame>
        <population>This outcome is reported for enrolled subjects where data is available.</population>
        <group_list>
          <group group_id="O1">
            <title>Edwards INTUITY Surgical Aortic Heart Valve</title>
            <description>Subjects who received an Edwards INTUITY surgical aortic heart valve.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Subjects With Edwards INTUITY Surgical Aortic Heart Valve Device Technical Success</title>
          <description>Device technical success is defined as the successful delivery and deployment of the aortic trial heart valve with maximum of two attempts and subject leaving the operating room (OR) with valve in place.</description>
          <population>This outcome is reported for enrolled subjects where data is available.</population>
          <units>Percentage of subjects</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="888"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="94.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Subjects With Edwards INTUITY Surgical Heart Valve Procedural Success</title>
        <description>Procedural success is defined as device technical success followed by the absence of adverse events resulting in device reoperation implant of permanent pacemaker (with baseline sinus rhythm and no other pre-existing conduction issues), or valve-related death within discharge or 10 days post index procedure, whichever comes first.</description>
        <time_frame>Day of procedure through discharge or 10 days post index procedure, whichever comes first.</time_frame>
        <population>This outcome is reported for enrolled subjects where data is available.</population>
        <group_list>
          <group group_id="O1">
            <title>Edwards INTUITY Surgical Aortic Heart Valve</title>
            <description>Subjects who received an Edwards INTUITY surgical aortic heart valve.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Subjects With Edwards INTUITY Surgical Heart Valve Procedural Success</title>
          <description>Procedural success is defined as device technical success followed by the absence of adverse events resulting in device reoperation implant of permanent pacemaker (with baseline sinus rhythm and no other pre-existing conduction issues), or valve-related death within discharge or 10 days post index procedure, whichever comes first.</description>
          <population>This outcome is reported for enrolled subjects where data is available.</population>
          <units>Percentage of subjects</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="886"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="94.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Average Amount of Time Subject Spent on Cardiopulmonary Bypass</title>
        <description>Surgical and hospitalization factors - Cardiopulmonary bypass time</description>
        <time_frame>Day of procedure</time_frame>
        <population>Data is not available for two subjects.</population>
        <group_list>
          <group group_id="O1">
            <title>Edwards INTUITY Surgical Aortic Heart Valve</title>
            <description>Subjects who received an INTUITY study surgical aortic heart valve.</description>
          </group>
        </group_list>
        <measure>
          <title>Average Amount of Time Subject Spent on Cardiopulmonary Bypass</title>
          <description>Surgical and hospitalization factors - Cardiopulmonary bypass time</description>
          <population>Data is not available for two subjects.</population>
          <units>Minutes</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="837"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="86.2" spread="37.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Average Subject Time on Cardiopulmonary Cross Clamp</title>
        <description>Surgical and hospitalization factors - Cardiopulmonary cross clamp time</description>
        <time_frame>Day of procedure</time_frame>
        <population>Data is not available for 3 subjects.</population>
        <group_list>
          <group group_id="O1">
            <title>Edwards INTUITY Surgical Aortic Heart Valve</title>
            <description>Subjects who received an INTUITY study surgical aortic heart valve.</description>
          </group>
        </group_list>
        <measure>
          <title>Average Subject Time on Cardiopulmonary Cross Clamp</title>
          <description>Surgical and hospitalization factors - Cardiopulmonary cross clamp time</description>
          <population>Data is not available for 3 subjects.</population>
          <units>Minutes</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="836"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="64.9" spread="29.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Average Number of Days Subjects Were in the Intensive Care Unit (ICU)</title>
        <description>Length of time surgical subjects were in the intensive care unit (ICU) after their heart valve replacement procedure.</description>
        <time_frame>Day of procedure through discharge from the hospital</time_frame>
        <population>Data is not available for 5 subjects.</population>
        <group_list>
          <group group_id="O1">
            <title>Edwards INTUITY Surgical Aortic Heart Valve</title>
            <description>Subjects who received an INTUITY study surgical aortic heart valve.</description>
          </group>
        </group_list>
        <measure>
          <title>Average Number of Days Subjects Were in the Intensive Care Unit (ICU)</title>
          <description>Length of time surgical subjects were in the intensive care unit (ICU) after their heart valve replacement procedure.</description>
          <population>Data is not available for 5 subjects.</population>
          <units>Days</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="834"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.1" spread="3.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Subject’s Percentage of Change at 1 Year From Baseline in New York Heart Association (NYHA) Class</title>
        <description>The New York Heart Association (NYHA) functional classification system relates symptoms to everyday activities and the patient's quality of life. Class I. Patients with cardiac disease but without resulting limitation of physical activity.
Class II. Patients with cardiac disease resulting in slight limitation of physical activity. They are comfortable at rest.
Class III. Patients with cardiac disease resulting in marked limitation of physical activity. They are comfortable at rest.
Class IV. Patients with cardiac disease resulting in inability to carry on any physical activity without discomfort.
Symptoms of heart failure or the anginal syndrome may be present even at rest.</description>
        <time_frame>Baseline and one year follow-up</time_frame>
        <population>This outcome is reported for subjects who received an Edwards INTUITY surgical aortic heart valve where data is available.</population>
        <group_list>
          <group group_id="O1">
            <title>Edwards INTUITY Surgical Aortic Heart Valve</title>
            <description>Subjects who received an INTUITY study surgical aortic heart valve.</description>
          </group>
        </group_list>
        <measure>
          <title>Subject’s Percentage of Change at 1 Year From Baseline in New York Heart Association (NYHA) Class</title>
          <description>The New York Heart Association (NYHA) functional classification system relates symptoms to everyday activities and the patient's quality of life. Class I. Patients with cardiac disease but without resulting limitation of physical activity.
Class II. Patients with cardiac disease resulting in slight limitation of physical activity. They are comfortable at rest.
Class III. Patients with cardiac disease resulting in marked limitation of physical activity. They are comfortable at rest.
Class IV. Patients with cardiac disease resulting in inability to carry on any physical activity without discomfort.
Symptoms of heart failure or the anginal syndrome may be present even at rest.</description>
          <population>This outcome is reported for subjects who received an Edwards INTUITY surgical aortic heart valve where data is available.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="546"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Improved at 1 Year</title>
                  <measurement_list>
                    <measurement group_id="O1" value="399"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Stayed the Same at 1 Year</title>
                  <measurement_list>
                    <measurement group_id="O1" value="129"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Worsened at 1 Year</title>
                  <measurement_list>
                    <measurement group_id="O1" value="18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Subject’s Average Gradient Measurements at 1 Year</title>
        <description>Hemodynamic performance - Mean and peak gradients evaluated by echocardiography</description>
        <time_frame>1 Year follow-up</time_frame>
        <population>This outcome is reported for subjects who received an Edwards INTUITY surgical aortic heart valve where data is available.</population>
        <group_list>
          <group group_id="O1">
            <title>Edwards INTUITY Surgical Aortic Heart Valve</title>
            <description>Subjects who received an INTUITY study surgical aortic heart valve.</description>
          </group>
        </group_list>
        <measure>
          <title>Subject’s Average Gradient Measurements at 1 Year</title>
          <description>Hemodynamic performance - Mean and peak gradients evaluated by echocardiography</description>
          <population>This outcome is reported for subjects who received an Edwards INTUITY surgical aortic heart valve where data is available.</population>
          <units>mmHg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="509"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Mean Gradient</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.3" spread="3.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Peak Gradient</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18.8" spread="7.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Subject’s Effective Orifice Area (EOA) Measurement at 1 Year</title>
        <description>Hemodynamic performance - Effective Orifice Area (EOA) evaluated by echocardiography</description>
        <time_frame>1 Year follow-up</time_frame>
        <population>This outcome is reported for subjects who received an Edwards INTUITY surgical aortic heart valve where data is available.</population>
        <group_list>
          <group group_id="O1">
            <title>Edwards INTUITY Surgical Aortic Heart Valve</title>
            <description>Subjects who received an INTUITY study surgical aortic heart valve.</description>
          </group>
        </group_list>
        <measure>
          <title>Subject’s Effective Orifice Area (EOA) Measurement at 1 Year</title>
          <description>Hemodynamic performance - Effective Orifice Area (EOA) evaluated by echocardiography</description>
          <population>This outcome is reported for subjects who received an Edwards INTUITY surgical aortic heart valve where data is available.</population>
          <units>Centimeters squared</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="491"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.7" spread="0.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Subject’s Effective Orifice Area Index (EOAI) Measurement at 1 Year</title>
        <description>Hemodynamic performance - Effective Orifice Area Index evaluated by echocardiography</description>
        <time_frame>1 year follow-up</time_frame>
        <population>This outcome is reported for subjects who received an Edwards INTUITY surgical aortic heart valve where data is available.</population>
        <group_list>
          <group group_id="O1">
            <title>Edwards INTUITY Surgical Aortic Heart Valve</title>
            <description>Subjects who received an INTUITY study surgical aortic heart valve.</description>
          </group>
        </group_list>
        <measure>
          <title>Subject’s Effective Orifice Area Index (EOAI) Measurement at 1 Year</title>
          <description>Hemodynamic performance - Effective Orifice Area Index evaluated by echocardiography</description>
          <population>This outcome is reported for subjects who received an Edwards INTUITY surgical aortic heart valve where data is available.</population>
          <units>centimeters squared/meters squared</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="488"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.8" spread="0.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Subject’s Performance Index Measurement at 1 Year</title>
        <description>Hemodynamic performance - Performance Index evaluated by echocardiography</description>
        <time_frame>1 Year follow-up</time_frame>
        <population>This outcome is reported for subjects who received an Edwards INTUITY surgical aortic heart valve where data is available.</population>
        <group_list>
          <group group_id="O1">
            <title>Edwards INTUITY Surgical Aortic Heart Valve</title>
            <description>Subjects who received an INTUITY study surgical aortic heart valve.</description>
          </group>
        </group_list>
        <measure>
          <title>Subject’s Performance Index Measurement at 1 Year</title>
          <description>Hemodynamic performance - Performance Index evaluated by echocardiography</description>
          <population>This outcome is reported for subjects who received an Edwards INTUITY surgical aortic heart valve where data is available.</population>
          <units>Centimeters squared/meters squared</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="491"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.9" spread="0.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Subject’s Cardiac Output Measurement at 1 Year</title>
        <description>Hemodynamic performance - Cardiac Output evaluated by echocardiography</description>
        <time_frame>1 Year follow-up</time_frame>
        <population>This outcome is reported for subjects who received an Edwards INTUITY surgical aortic heart valve where data is available.</population>
        <group_list>
          <group group_id="O1">
            <title>Edwards INTUITY Surgical Aortic Heart Valve</title>
            <description>Subjects who received an INTUITY study surgical aortic heart valve.</description>
          </group>
        </group_list>
        <measure>
          <title>Subject’s Cardiac Output Measurement at 1 Year</title>
          <description>Hemodynamic performance - Cardiac Output evaluated by echocardiography</description>
          <population>This outcome is reported for subjects who received an Edwards INTUITY surgical aortic heart valve where data is available.</population>
          <units>Liters/minutes</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="501"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.9" spread="1.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Subject’s Cardiac Index Measurement at 1 Year</title>
        <description>Hemodynamic performance - Cardiac index evaluated by echocardiography</description>
        <time_frame>1 Year follow-up</time_frame>
        <population>This outcome is reported for subjects who received an Edwards INTUITY surgical aortic heart valve where data is available.</population>
        <group_list>
          <group group_id="O1">
            <title>Edwards INTUITY Surgical Aortic Heart Valve</title>
            <description>Subjects who received an INTUITY study surgical aortic heart valve.</description>
          </group>
        </group_list>
        <measure>
          <title>Subject’s Cardiac Index Measurement at 1 Year</title>
          <description>Hemodynamic performance - Cardiac index evaluated by echocardiography</description>
          <population>This outcome is reported for subjects who received an Edwards INTUITY surgical aortic heart valve where data is available.</population>
          <units>Liters/minutes/meters squared</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="497"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.4" spread="0.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Amount of Aortic Valvular Regurgitation in Subjects at 1 Year by Valve Size</title>
        <description>Hemodynamic performance - Aortic valvular regurgitation evaluated by echocardiography</description>
        <time_frame>1 Year follow-up</time_frame>
        <population>This outcome is reported for subjects who received an Edwards INTUITY surgical aortic heart valve where data is available. Each subject can only receive one valve and results are presented by valve size. The number of participants in each of the valve sizes totals up to the overall number analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>Edwards INTUITY Surgical Aortic Heart Valve</title>
            <description>Subjects who received an INTUITY study surgical aortic heart valve.</description>
          </group>
        </group_list>
        <measure>
          <title>Amount of Aortic Valvular Regurgitation in Subjects at 1 Year by Valve Size</title>
          <description>Hemodynamic performance - Aortic valvular regurgitation evaluated by echocardiography</description>
          <population>This outcome is reported for subjects who received an Edwards INTUITY surgical aortic heart valve where data is available. Each subject can only receive one valve and results are presented by valve size. The number of participants in each of the valve sizes totals up to the overall number analyzed.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="521"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Valve size - 19 mm</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="38"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>None (0)/Trival (+1)</title>
                  <measurement_list>
                    <measurement group_id="O1" value="33"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Mild (+2)</title>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Moderate (+3)</title>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Severe (+4)</title>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Valve size - 21 mm</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="118"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>None (0)/Trival (+1)</title>
                  <measurement_list>
                    <measurement group_id="O1" value="114"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Mild (+2)</title>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Moderate (+3)</title>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Severe (+4)</title>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Valve size - 23 mm</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="166"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>None (0)/Trival (+1)</title>
                  <measurement_list>
                    <measurement group_id="O1" value="148"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Mild (+2)</title>
                  <measurement_list>
                    <measurement group_id="O1" value="13"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Moderate (+3)</title>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Severe (+4)</title>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Valve size - 25 mm</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="137"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>None (0)/Trival (+1)</title>
                  <measurement_list>
                    <measurement group_id="O1" value="122"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Mild (+2)</title>
                  <measurement_list>
                    <measurement group_id="O1" value="14"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Moderate (+3)</title>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Severe (+4)</title>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Valve size - 27 mm</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="62"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>None (0)/Trival (+1)</title>
                  <measurement_list>
                    <measurement group_id="O1" value="58"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Mild (+2)</title>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Moderate (+3)</title>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Severe (+4)</title>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Subject’s Average Score at Baseline and 1 Year on the Quality of Life Survey</title>
        <description>The Medical Outcomes Study Short-Form 12 (SF-12) - physical and metal states. The SF-12 questionnaire scale ranges from 100, which reflects the best health status to 0, which reflects the worst health status.</description>
        <time_frame>Baseline and one year follow-up</time_frame>
        <population>This outcome is reported for subjects who received an Edwards INTUITY surgical aortic heart valve where data is available.</population>
        <group_list>
          <group group_id="O1">
            <title>Edwards INTUITY Surgical Aortic Heart Valve</title>
            <description>Subjects who received an INTUITY study surgical aortic heart valve.</description>
          </group>
        </group_list>
        <measure>
          <title>Subject’s Average Score at Baseline and 1 Year on the Quality of Life Survey</title>
          <description>The Medical Outcomes Study Short-Form 12 (SF-12) - physical and metal states. The SF-12 questionnaire scale ranges from 100, which reflects the best health status to 0, which reflects the worst health status.</description>
          <population>This outcome is reported for subjects who received an Edwards INTUITY surgical aortic heart valve where data is available.</population>
          <units>Units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="526"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Mental Health - Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="51.3" spread="9.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Mental Health - 1 year follow-up</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="54.3" spread="8.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Physical Health - Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="41.8" spread="10.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Physical Health - 1 year follow-up</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="47.6" spread="9.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Subject’s Average White Blood Cell Count at 1 Year</title>
        <description>Laboratory analysis of White Blood Cell Count on blood drawn from subject.</description>
        <time_frame>1 Year follow-up</time_frame>
        <population>This outcome is reported for subjects who received an Edwards INTUITY surgical aortic heart valve where data is available.</population>
        <group_list>
          <group group_id="O1">
            <title>Edwards INTUITY Surgical Aortic Heart Valve</title>
            <description>Subjects who received an INTUITY study surgical aortic heart valve.</description>
          </group>
        </group_list>
        <measure>
          <title>Subject’s Average White Blood Cell Count at 1 Year</title>
          <description>Laboratory analysis of White Blood Cell Count on blood drawn from subject.</description>
          <population>This outcome is reported for subjects who received an Edwards INTUITY surgical aortic heart valve where data is available.</population>
          <units>10^3 cells/microliters</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="538"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.32" spread="3.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Subject’s Average Red Blood Cell Count at 1 Year</title>
        <description>Laboratory analysis of Red Blood Cell Count of blood drawn from subject.</description>
        <time_frame>1 Year follow-up</time_frame>
        <population>This outcome is reported for subjects who received an Edwards INTUITY surgical aortic heart valve where data is available.</population>
        <group_list>
          <group group_id="O1">
            <title>Edwards INTUITY Surgical Aortic Heart Valve</title>
            <description>Subjects who received an INTUITY study surgical aortic heart valve.</description>
          </group>
        </group_list>
        <measure>
          <title>Subject’s Average Red Blood Cell Count at 1 Year</title>
          <description>Laboratory analysis of Red Blood Cell Count of blood drawn from subject.</description>
          <population>This outcome is reported for subjects who received an Edwards INTUITY surgical aortic heart valve where data is available.</population>
          <units>10^6 cells/microliters</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="538"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.44" spread="0.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Subject’s Average Hematocrit Percentage at 1 Year</title>
        <description>Laboratory analysis of Hematocrit of blood drawn from subject.</description>
        <time_frame>1 Year follow-up</time_frame>
        <population>This outcome is reported for subjects who received an Edwards INTUITY surgical aortic heart valve where data is available.</population>
        <group_list>
          <group group_id="O1">
            <title>Edwards INTUITY Surgical Aortic Heart Valve</title>
            <description>Subjects who received an INTUITY study surgical aortic heart valve.</description>
          </group>
        </group_list>
        <measure>
          <title>Subject’s Average Hematocrit Percentage at 1 Year</title>
          <description>Laboratory analysis of Hematocrit of blood drawn from subject.</description>
          <population>This outcome is reported for subjects who received an Edwards INTUITY surgical aortic heart valve where data is available.</population>
          <units>Percentage of RBC</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="538"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="40.1" spread="4.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Subject’s Average Hemoglobin Percentage at 1 Year</title>
        <description>Laboratory analysis of Hemoglobin of blood drawn from subject.</description>
        <time_frame>1 Year follow-up</time_frame>
        <population>This outcome is reported for subjects who received an Edwards INTUITY surgical aortic heart valve where data is available.</population>
        <group_list>
          <group group_id="O1">
            <title>Edwards INTUITY Surgical Aortic Heart Valve</title>
            <description>Subjects who received an INTUITY study surgical aortic heart valve.</description>
          </group>
        </group_list>
        <measure>
          <title>Subject’s Average Hemoglobin Percentage at 1 Year</title>
          <description>Laboratory analysis of Hemoglobin of blood drawn from subject.</description>
          <population>This outcome is reported for subjects who received an Edwards INTUITY surgical aortic heart valve where data is available.</population>
          <units>g/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="538"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13.29" spread="1.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Subject’s Average Plasma Free Hemoglobin at 1 Year</title>
        <description>Laboratory Analysis of Plasma Free Hemoglobin of blood drawn from subject.</description>
        <time_frame>1 Year follow-up</time_frame>
        <population>This outcome is reported for subjects who received an Edwards INTUITY surgical aortic heart valve where data is available.</population>
        <group_list>
          <group group_id="O1">
            <title>Edwards INTUITY Surgical Aortic Heart Valve</title>
            <description>Subjects who received an INTUITY study surgical aortic heart valve.</description>
          </group>
        </group_list>
        <measure>
          <title>Subject’s Average Plasma Free Hemoglobin at 1 Year</title>
          <description>Laboratory Analysis of Plasma Free Hemoglobin of blood drawn from subject.</description>
          <population>This outcome is reported for subjects who received an Edwards INTUITY surgical aortic heart valve where data is available.</population>
          <units>mg/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="466"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12.23" spread="13.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Events occurring from the day of aortic heart valve surgery through 2 years post implant.</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Edwards INTUITY Surgical Aortic Heart Valve</title>
          <description>Subjects who received an INTUITY study surgical aortic heart valve.</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="25" subjects_at_risk="839"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="533" subjects_at_risk="839"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anemia - Bleeding Related - Minor</sub_title>
                <counts group_id="E1" subjects_affected="30" subjects_at_risk="839"/>
              </event>
              <event>
                <sub_title>ANEMIA - BLEEDING RELATED - MAJOR</sub_title>
                <counts group_id="E1" subjects_affected="22" subjects_at_risk="839"/>
              </event>
              <event>
                <sub_title>THROMBOCYTOPENIA - NON-HEPARIN INDUCED</sub_title>
                <counts group_id="E1" subjects_affected="18" subjects_at_risk="839"/>
              </event>
              <event>
                <sub_title>BLEEDING - CARDIOVASCULAR - MAJOR</sub_title>
                <counts group_id="E1" subjects_affected="17" subjects_at_risk="839"/>
              </event>
              <event>
                <sub_title>ANEMIA - NON-BLEEDING RELATED</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="839"/>
              </event>
              <event>
                <sub_title>BLEEDING - CARDIOVASCULAR - MINOR</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="839"/>
              </event>
              <event>
                <sub_title>BLEEDING - GASTROINTESTINAL UPPER - MAJOR</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="839"/>
              </event>
              <event>
                <sub_title>BLOOD SEPSIS</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="839"/>
              </event>
              <event>
                <sub_title>BLEEDING - GASTROINTESTINAL LOWER - MINOR</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="839"/>
              </event>
              <event>
                <sub_title>BLEEDING - GASTROINTESTINAL LOWER - MAJOR</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="839"/>
              </event>
              <event>
                <sub_title>BLOOD/LYMPHATIC - OTHER</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="839"/>
              </event>
              <event>
                <sub_title>THROMBOCYTOPENIA - HEPARIN INDUCED (HIT)</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="839"/>
              </event>
              <event>
                <sub_title>BLEEDING - GASTROINTESTINAL UPPER - MINOR</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="839"/>
              </event>
              <event>
                <sub_title>BLEEDING - GENITOURINARY - MINOR</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="839"/>
              </event>
              <event>
                <sub_title>BLEEDING - NEUROLOGICAL - MAJOR (E.G. CVA)</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="839"/>
              </event>
              <event>
                <sub_title>BLEEDING - PULMONARY/RESPIRATORY - MAJOR (E.G. HEMOTHORAX)</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="839"/>
              </event>
              <event>
                <sub_title>BLEEDING - GENITOURINARY - MAJOR</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="839"/>
              </event>
              <event>
                <sub_title>BLEEDING - MUSCULOSKELETAL/DERMATOLOGICAL - MINOR (E.G. ECCHYMOSIS)</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="839"/>
              </event>
              <event>
                <sub_title>BLEEDING - PERIPHERAL VASCULAR - MAJOR (E.G. NOSEBLEEDS; HEMATOMAS)</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="839"/>
              </event>
              <event>
                <sub_title>BLEEDING - PULMONARY/RESPIRATORY - MINOR (E.G. HEMOTHORAX)</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="839"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>ARRHYTHMIA - AV BLOCK - 3RD DEGREE</sub_title>
                <counts group_id="E1" subjects_affected="77" subjects_at_risk="839"/>
              </event>
              <event>
                <sub_title>ARRHYTHMIA - PAROXYSMAL ATRIAL FIBRILLATION (PAF)</sub_title>
                <counts group_id="E1" subjects_affected="63" subjects_at_risk="839"/>
              </event>
              <event>
                <sub_title>ARRHYTHMIA - PERSISTENT ATRIAL FIBRILLATION</sub_title>
                <counts group_id="E1" subjects_affected="49" subjects_at_risk="839"/>
              </event>
              <event>
                <sub_title>ARRHYTHMIA - ATRIAL FLUTTER</sub_title>
                <counts group_id="E1" subjects_affected="24" subjects_at_risk="839"/>
              </event>
              <event>
                <sub_title>ARRHYTHMIA - OTHER</sub_title>
                <counts group_id="E1" subjects_affected="23" subjects_at_risk="839"/>
              </event>
              <event>
                <sub_title>ARRHYTHMIA - BRADYCARDIA</sub_title>
                <counts group_id="E1" subjects_affected="16" subjects_at_risk="839"/>
              </event>
              <event>
                <sub_title>ARRHYTHMIA - AV BLOCK - 2ND DEGREE</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="839"/>
              </event>
              <event>
                <sub_title>ARRHYTHMIA - BUNDLE BRANCH BLOCK - LEFT</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="839"/>
              </event>
              <event>
                <sub_title>ARRHYTHMIA - TACHY-BRADYCARDIA</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="839"/>
              </event>
              <event>
                <sub_title>ARRHYTHMIA - TACHYCARDIA - VENTRICULAR</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="839"/>
              </event>
              <event>
                <sub_title>ARRHYTHMIA - AV BLOCK - 1ST DEGREE</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="839"/>
              </event>
              <event>
                <sub_title>ARRHYTHMIA - TACHYCARDIA - NON-VENTRICULAR</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="839"/>
              </event>
              <event>
                <sub_title>ARRHYTHMIA - BUNDLE BRANCH BLOCK - RIGHT</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="839"/>
              </event>
              <event>
                <sub_title>ARRHYTHMIA - SUPRAVENTRICULAR TACHYCARDIA (SVT)</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="839"/>
              </event>
              <event>
                <sub_title>ARRHYTHMIA - PAROXYSMAL ATRIAL TACHYCARDIA (PAT)</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="839"/>
              </event>
              <event>
                <sub_title>ARRHYTHMIA - PERMANENT ATRIAL FIBRILLATION</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="839"/>
              </event>
              <event>
                <sub_title>CARDIOVASCULAR - OTHER</sub_title>
                <counts group_id="E1" subjects_affected="40" subjects_at_risk="839"/>
              </event>
              <event>
                <sub_title>HEART FAILURE - ACUTE</sub_title>
                <counts group_id="E1" subjects_affected="26" subjects_at_risk="839"/>
              </event>
              <event>
                <sub_title>HYPOTENSION</sub_title>
                <counts group_id="E1" subjects_affected="18" subjects_at_risk="839"/>
              </event>
              <event>
                <sub_title>HEART FAILURE - CHRONIC (CHF)</sub_title>
                <counts group_id="E1" subjects_affected="17" subjects_at_risk="839"/>
              </event>
              <event>
                <sub_title>PERICARDIAL EFFUSION - MAJOR</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="839"/>
              </event>
              <event>
                <sub_title>CARDIAC ARREST</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="839"/>
              </event>
              <event>
                <sub_title>HYPERTENSION - SYSTEMIC</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="839"/>
              </event>
              <event>
                <sub_title>CARDIOGENIC SHOCK</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="839"/>
              </event>
              <event>
                <sub_title>ANGINA, UNSTABLE</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="839"/>
              </event>
              <event>
                <sub_title>MYOCARDIAL INFARCTION</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="839"/>
              </event>
              <event>
                <sub_title>PERICARDIAL TAMPONADE</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="839"/>
              </event>
              <event>
                <sub_title>PERICARDITIS</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="839"/>
              </event>
              <event>
                <sub_title>ANGINA, STABLE</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="839"/>
              </event>
              <event>
                <sub_title>AORTIC DISSECTION</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="839"/>
              </event>
              <event>
                <sub_title>PERICARDIAL EFFUSION - MINOR</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="839"/>
              </event>
              <event>
                <sub_title>CARDIAC DECOMPENSATION</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="839"/>
              </event>
              <event>
                <sub_title>ENDOCARDITIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="839"/>
              </event>
              <event>
                <sub_title>PERFORATION - VENTRICULAR</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="839"/>
              </event>
              <event>
                <sub_title>REGURGITATION - TRICUSPID-CENTRAL/TRANSVALVULAR +4</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="839"/>
              </event>
              <event>
                <sub_title>REGURGITATION - AORTIC-CENTRAL/TRANSVALVULAR +4</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="839"/>
              </event>
              <event>
                <sub_title>REGURGITATION - MITRAL-CENTRAL/TRANSVALVULAR +4</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="839"/>
              </event>
              <event>
                <sub_title>REGURGITATION - MITRAL-INDETERMINATE +4</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="839"/>
              </event>
              <event>
                <sub_title>THROMBOEMBOLIC EVENT - STROKE</sub_title>
                <counts group_id="E1" subjects_affected="22" subjects_at_risk="839"/>
              </event>
              <event>
                <sub_title>THROMBOEMBOLIC EVENT - TRANSIENT ISCHEMIC ATTACK (TIA)</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="839"/>
              </event>
              <event>
                <sub_title>THROMBOEMBOLIC EVENT - OTHER - CENTRAL - NO PARESIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="839"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>VISION DISORDER</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="839"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>GASTROINTESTINAL - OTHER</sub_title>
                <counts group_id="E1" subjects_affected="40" subjects_at_risk="839"/>
              </event>
              <event>
                <sub_title>BILIARY (GALLBLADDER)</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="839"/>
              </event>
              <event>
                <sub_title>GASTROINTESTINAL - INFECTION</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="839"/>
              </event>
              <event>
                <sub_title>PANCREATIC COMPLICATION</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="839"/>
              </event>
              <event>
                <sub_title>HEPATIC COMPLICATION - OTHER</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="839"/>
              </event>
              <event>
                <sub_title>LIVER FAILURE - ACUTE</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="839"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>NSD - PARAVALVULAR LEAK +3</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="839"/>
              </event>
              <event>
                <sub_title>NSD - PARAVALVULAR LEAK +4</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="839"/>
              </event>
              <event>
                <sub_title>NSD - PARAVALVULAR LEAK WITH HEMOLYSIS</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="839"/>
              </event>
              <event>
                <sub_title>NSD - PARAVALVULAR LEAK +2</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="839"/>
              </event>
              <event>
                <sub_title>NONSPECIFIC, UNKNOWN, OR OTHER BODY SYSTEM - OTHER COMPLICATION</sub_title>
                <counts group_id="E1" subjects_affected="76" subjects_at_risk="839"/>
              </event>
              <event>
                <sub_title>CANCER - NEWLY DIAGNOSED</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="839"/>
              </event>
              <event>
                <sub_title>FEVER - UNKNOWN ORIGIN</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="839"/>
              </event>
              <event>
                <sub_title>MULTI-SYSTEM ORGAN FAILURE</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="839"/>
              </event>
              <event>
                <sub_title>CANCER - PROGRESSION OF UNDERLYING DISEASE</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="839"/>
              </event>
              <event>
                <sub_title>ALLERGIC REACTION - MEDICATION RELATED</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="839"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>MUSCULAR SKELETAL/DERMATOLOGIC - OTHER</sub_title>
                <counts group_id="E1" subjects_affected="39" subjects_at_risk="839"/>
              </event>
              <event>
                <sub_title>BONE FRACTURE/BREAK</sub_title>
                <counts group_id="E1" subjects_affected="15" subjects_at_risk="839"/>
              </event>
              <event>
                <sub_title>WOUND INFECTION - OTHER</sub_title>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="839"/>
              </event>
              <event>
                <sub_title>INFECTION/INFLAMMATION - OTHER</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="839"/>
              </event>
              <event>
                <sub_title>STERNAL WOUND/THORACIC INFECTION</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="839"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>PSYCHIATRIC - OTHER</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="839"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>RENAL FAILURE - ACUTE</sub_title>
                <counts group_id="E1" subjects_affected="22" subjects_at_risk="839"/>
              </event>
              <event>
                <sub_title>URINARY TRACT INFECTION (UTI)</sub_title>
                <counts group_id="E1" subjects_affected="17" subjects_at_risk="839"/>
              </event>
              <event>
                <sub_title>GENITOURINARY - OTHER</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="839"/>
              </event>
              <event>
                <sub_title>RENAL - OTHER</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="839"/>
              </event>
              <event>
                <sub_title>RENAL DYSFUNCTION</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="839"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>RESPIRATORY FAILURE - OTHER</sub_title>
                <counts group_id="E1" subjects_affected="25" subjects_at_risk="839"/>
              </event>
              <event>
                <sub_title>PLEURAL EFFUSION - RIGHT</sub_title>
                <counts group_id="E1" subjects_affected="24" subjects_at_risk="839"/>
              </event>
              <event>
                <sub_title>PLEURAL EFFUSION - BILATERAL</sub_title>
                <counts group_id="E1" subjects_affected="20" subjects_at_risk="839"/>
              </event>
              <event>
                <sub_title>RESPIRATORY INFECTION - PNEUMONIA</sub_title>
                <counts group_id="E1" subjects_affected="20" subjects_at_risk="839"/>
              </event>
              <event>
                <sub_title>PLEURAL EFFUSION - LEFT</sub_title>
                <counts group_id="E1" subjects_affected="15" subjects_at_risk="839"/>
              </event>
              <event>
                <sub_title>PULMONARY/RESPIRATORY - OTHER</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="839"/>
              </event>
              <event>
                <sub_title>RESPIRATORY DYSFUNCTION/INSUFFICIENCY</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="839"/>
              </event>
              <event>
                <sub_title>RESPIRATORY FAILURE - PNEUMONIA</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="839"/>
              </event>
              <event>
                <sub_title>HYPOXEMIA</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="839"/>
              </event>
              <event>
                <sub_title>PNEUMOTHORAX</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="839"/>
              </event>
              <event>
                <sub_title>RESPIRATORY FAILURE - COPD</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="839"/>
              </event>
              <event>
                <sub_title>RESPIRATORY FAILURE - PNEUMOTHORAX</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="839"/>
              </event>
              <event>
                <sub_title>RESPIRATORY INFECTION - UPPER (URI)</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="839"/>
              </event>
              <event>
                <sub_title>PULMONARY EDEMA</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="839"/>
              </event>
              <event>
                <sub_title>PULMONARY EMBOLISM - BILATERAL</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="839"/>
              </event>
              <event>
                <sub_title>PULMONARY EMBOLISM - RIGHT</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="839"/>
              </event>
              <event>
                <sub_title>RESPIRATORY FAILURE - ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS)</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="839"/>
              </event>
              <event>
                <sub_title>RESPIRATORY FAILURE - ASTHMA</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="839"/>
              </event>
              <event>
                <sub_title>ATELECTASIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="839"/>
              </event>
              <event>
                <sub_title>PULMONARY EMBOLISM - LEFT</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="839"/>
              </event>
              <event>
                <sub_title>RESPIRATORY FAILURE - HEMOTHORAX</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="839"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>VASCULAR - OTHER</sub_title>
                <counts group_id="E1" subjects_affected="17" subjects_at_risk="839"/>
              </event>
              <event>
                <sub_title>VASCULAR - DEEP VEIN THROMBOSIS (DVT)</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="839"/>
              </event>
              <event>
                <sub_title>VASCULAR - ACCESS SITE COMPLICATION</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="839"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="800" subjects_at_risk="839"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>THROMBOCYTOPENIA - NON-HEPARIN INDUCED</sub_title>
                <counts group_id="E1" subjects_affected="409" subjects_at_risk="839"/>
              </event>
              <event>
                <sub_title>BLOOD/LYMPHATIC - OTHER</sub_title>
                <counts group_id="E1" subjects_affected="200" subjects_at_risk="839"/>
              </event>
              <event>
                <sub_title>ANEMIA - BLEEDING RELATED - MINOR</sub_title>
                <counts group_id="E1" subjects_affected="174" subjects_at_risk="839"/>
              </event>
              <event>
                <sub_title>ANEMIA - NON-BLEEDING RELATED</sub_title>
                <counts group_id="E1" subjects_affected="52" subjects_at_risk="839"/>
              </event>
              <event>
                <sub_title>ANEMIA - BLEEDING RELATED - MAJOR</sub_title>
                <counts group_id="E1" subjects_affected="45" subjects_at_risk="839"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>ARRHYTHMIA - PAROXYSMAL ATRIAL FIBRILLATION (PAF)</sub_title>
                <counts group_id="E1" subjects_affected="239" subjects_at_risk="839"/>
              </event>
              <event>
                <sub_title>ARRHYTHMIA - BUNDLE BRANCH BLOCK - LEFT</sub_title>
                <counts group_id="E1" subjects_affected="234" subjects_at_risk="839"/>
              </event>
              <event>
                <sub_title>ARRHYTHMIA - AV BLOCK - 1ST DEGREE</sub_title>
                <counts group_id="E1" subjects_affected="159" subjects_at_risk="839"/>
              </event>
              <event>
                <sub_title>ARRHYTHMIA - OTHER</sub_title>
                <counts group_id="E1" subjects_affected="159" subjects_at_risk="839"/>
              </event>
              <event>
                <sub_title>ARRHYTHMIA - BRADYCARDIA</sub_title>
                <counts group_id="E1" subjects_affected="97" subjects_at_risk="839"/>
              </event>
              <event>
                <sub_title>ARRHYTHMIA - BUNDLE BRANCH BLOCK - RIGHT</sub_title>
                <counts group_id="E1" subjects_affected="59" subjects_at_risk="839"/>
              </event>
              <event>
                <sub_title>HYPOTENSION</sub_title>
                <counts group_id="E1" subjects_affected="141" subjects_at_risk="839"/>
              </event>
              <event>
                <sub_title>CARDIOVASCULAR - OTHER</sub_title>
                <counts group_id="E1" subjects_affected="76" subjects_at_risk="839"/>
              </event>
              <event>
                <sub_title>HYPERTENSION - SYSTEMIC</sub_title>
                <counts group_id="E1" subjects_affected="49" subjects_at_risk="839"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>GASTROINTESTINAL - OTHER</sub_title>
                <counts group_id="E1" subjects_affected="66" subjects_at_risk="839"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>NONSPECIFIC, UNKNOWN, OR OTHER BODY SYSTEM - OTHER COMPLICATION</sub_title>
                <counts group_id="E1" subjects_affected="153" subjects_at_risk="839"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>MUSCULAR SKELETAL/DERMATOLOGIC - OTHER</sub_title>
                <counts group_id="E1" subjects_affected="74" subjects_at_risk="839"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>PSYCHIATRIC - OTHER</sub_title>
                <counts group_id="E1" subjects_affected="45" subjects_at_risk="839"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>URINARY TRACT INFECTION (UTI)</sub_title>
                <counts group_id="E1" subjects_affected="48" subjects_at_risk="839"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>ATELECTASIS</sub_title>
                <counts group_id="E1" subjects_affected="309" subjects_at_risk="839"/>
              </event>
              <event>
                <sub_title>PLEURAL EFFUSION - BILATERAL</sub_title>
                <counts group_id="E1" subjects_affected="54" subjects_at_risk="839"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>PI can't publish/present on overall study results not yet published but may publish his own data subject to EW review prior to submission/presentation, but data analyses of site-specific results can occur only in intervals as specified in the CTA. Publication/presentation of the PI’s site-specific results of devices which haven't been market released and which still may be undergoing development, shall not include claims of device safety/effectiveness and will require the review/approval of EW.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Mary Edwards, VP Clinical and Regulatory Affairs, HVT</name_or_title>
      <organization>Edwards Lifesciences, LLC</organization>
      <phone>949-250-2500 ext 1536</phone>
      <email>mary_edwards@edwards.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

